Patients with EGFR-mutant NSCLC that transforms into small cell lung cancer show poor responses to new therapies like tarlatamab, which are highly effective in de novo small cell cancer. This highlights a distinct biology that requires different therapeutic strategies and dedicated clinical trials.

Features like brain metastases or p53 co-mutations are considered high-risk. However, about 75% of patients have at least one such factor, making the "high-risk" profile the norm, not the exception, and reinforcing the need for upfront combination therapy.

Instead of creating therapies for hundreds of specific driver mutations, which vary widely between patients, Earli's platform targets downstream commonalities—the "hallmarks of cancer" like rapid cell proliferation. These pathways are where diverse mutations converge, creating a more universal and reliable target across different cancers.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

The same cancer-driving mutation behaves differently depending on the cell's internal "wiring." For example, a drug targeting a mutation works in melanoma but induces resistance in colorectal cancer due to a bypass pathway. This cellular context is why genetic data alone is insufficient.

The characteristic that makes stem cells invaluable—their ability to self-renew for a lifetime—is the same immortalization program that cancer cells hijack to grow without constraint. This highlights cancer's parasitic relationship with a fundamental biological process needed for survival.

Cellular senescence is a biological process that permanently halts cell division. Contrary to being just a sign of aging, its primary function is to prevent damaged cells from becoming cancerous. It's a protective measure that stops unchecked proliferation when a cell cannot repair its own damage or undergo programmed cell death.

A tumor can be viewed as an evolving system within the body's environment. It progresses from stage to stage by "ratcheting up" its functional information—its ability to survive and grow. This evolutionary framework could inspire novel cancer treatments.

Targeting the MYC cancer protein presents a dual challenge. Biologically, it's vital for healthy cells, creating a high risk of toxicity. Biophysically, its disordered, 'floppy' structure lacks the defined pockets that traditional drugs need to bind to, making it a 'holy grail' target.